WVE stock forecast, quote, news & analysis
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health... Show more
Why Wave Life Sciences (WVE) Is Down -52% in the Last 30 Days
Key Takeaways
- WVE stock plunged approximately -52% over the past 30 days, driven primarily by disappointing high-dose data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 on March 26, which erased prior gains from positive initial results.
- Over the past quarter, shares declined around -61%, reflecting high volatility in biotech sentiment amid clinical trial outcomes and broader sector pressures on clinical-stage firms.
- Key drivers include mixed clinical data on WVE-007 showing fat loss but no dose response at higher levels, Q4 2025 earnings miss on EPS despite revenue beat, and analyst price target adjustments.
- Persistent cash burn and reliance on partnerships like GSK highlight funding risks, though a strong cash position supports operations into 2028.
- RNA medicines platform remains differentiated, but investor focus has shifted to execution risks in obesity and rare disease programs.
Wave Life Sciences (WVE) Company Overview and Market Position
Wave Life Sciences Ltd. (WVE) is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of ribonucleic acid (RNA) medicines. The company leverages its proprietary PRISM platform, which integrates multiple RNA-targeting modalities—such as RNA interference (RNAi), RNA editing, splicing, and antisense silencing—with advanced chemistry and human genetics insights to address rare and prevalent disorders.
Wave's core business model focuses on advancing a pipeline targeting genetically defined diseases, including alpha-1 antitrypsin deficiency (AATD), Duchenne muscular dystrophy (DMD), Huntington's disease (HD), obesity, and liver disease. Key programs include WVE-006 (RNA editing for AATD), WVE-007 (GalNAc-conjugated siRNA for obesity), and WVE-N531 (exon-skipping for DMD). The firm collaborates with partners like GlaxoSmithKline (GSK) for oligonucleotide therapeutics, providing milestone payments and royalties.
In the competitive RNA therapeutics landscape dominated by players like Alnylam Pharmaceuticals and Ionis Pharmaceuticals, Wave differentiates through stereopure oligonucleotides and GalNAc conjugation for liver-targeted delivery. Recent stock behavior underscores exposure to clinical binary risks, with pipeline setbacks amplifying volatility in a sector sensitive to trial data and funding dynamics.
Wave Life Sciences (WVE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, WVE stock has fallen sharply by -52%, closing near $6.62 from around $13.85 on March 2. The decline was marked by extreme volatility, highlighted by a 50% single-day drop on March 26 amid massive trading volume exceeding 50 million shares—over ten times the average.
For the past quarter, shares are down approximately -61%, trading from about $17.00 at year-end 2025 to the current level. Movement has been trend-driven downward after an initial post-earnings stabilization, punctuated by sharp swings tied to clinical news. The stock remains below its 50-day moving average of $12.81 and 200-day moving average of $10.19, reflecting a range-bound yet bearish pattern within a 52-week range of $5.02 to $21.73.
What Drove WVE Stock Price in the Last 30 Days
The primary catalyst for WVE's 30-day plunge was the March 26 release of interim Phase 1 INLIGHT trial data for WVE-007, an investigational GalNAc-siRNA targeting INHBE for obesity. While the 240 mg dose showed promising 14.3% placebo-adjusted visceral fat reduction at six months with lean muscle preservation—echoing GLP-1-like body composition benefits—the higher 400 mg dose delivered only 0.9% weight loss at three months and no clear superiority, disappointing investors expecting dose proportionality.
This triggered a 50%+ selloff, with volume spiking to 50 million shares as sentiment soured on WVE-007's competitive positioning against established GLP-1 drugs. Analyst reactions were mixed: firms like BofA and Wells Fargo cut targets (e.g., $38 to $21, $27 to $13) citing efficacy concerns, while others like Mizuho maintained Buy ratings emphasizing lower-dose potential. Broader biotech sector weakness and profit-taking from prior obesity hype exacerbated the move.
What Drove WVE Stock Performance Over the Last Quarter
The quarter's -61% decline stemmed from a volatile narrative shift in Wave's obesity program and ongoing clinical uncertainties. Early momentum faded after December 2025's positive initial WVE-007 data drove shares to $21.73, but Q4 2025 earnings on February 26—reporting a $0.30 EPS miss (vs. -$0.28 expected) and $17.2 million revenue (beat but down YoY due to Takeda termination)—tempered enthusiasm amid $53.2 million net loss.
Sustained pressure mounted from high cash burn ($204 million full-year net loss) and regulatory hurdles, compounded by macroeconomic caution toward unprofitable biotechs amid rising rates. Institutional selling and short interest contributed, though GSK milestones provided some support. Cumulative impact favored bears, with beta at -1.65 underscoring amplified sector downside.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from among hundreds that trade thousands of tickers across various markets. This curated section highlights bots with the strongest recent returns, relevance to current market trends, and consistent performance metrics like win rate, average gain, and risk-adjusted Sharpe ratio. Strategies range from momentum and mean reversion on short-term intraday timeframes to value and growth investing over swing or long-term horizons, often outperforming benchmarks in volatile conditions like biotech swings. Users can explore detailed backtests, live signals, and subscription options to deploy these bots on their brokerage accounts for automated stock analysis and execution. Check out the Trending AI Robots today to enhance your trading with data-driven intelligence.
WVE Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming clinical milestones, including six-month 240 mg and three-month 400 mg follow-up data from INLIGHT, Phase 2a multidose initiation for WVE-007 in higher-BMI patients, and new trials as incretin add-on or post-incretin maintenance—all slated for 2026. RestorAATion-2 updates for WVE-006 in AATD (400 mg multidose in Q1 2026, FDA feedback mid-year on accelerated approval) and CTA filing for WVE-008 in PNPLA3 liver disease represent key RNA editing catalysts.
Quarterly earnings (next around May 2026) will reveal cash burn progress against the $602 million runway into 3Q 2028, plus GSK milestones. Macro trends in obesity drug competition, biotech funding environment, and regulatory developments could sway sentiment, alongside risks from trial delays or dilution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
WVE's RSI Oscillator climbs out of oversold territory
The RSI Indicator for WVE moved out of oversold territory on April 13, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In of the 23 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 10, 2026. You may want to consider a long position or call options on WVE as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for WVE just turned positive on April 14, 2026. Looking at past instances where WVE's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where WVE advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
WVE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
WVE moved below its 50-day moving average on March 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WVE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for WVE entered a downward trend on April 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.657) is normal, around the industry mean (26.524). P/E Ratio (0.000) is within average values for comparable stocks, (45.776). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.765). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (28.902) is also within normal values, averaging (321.098).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. WVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of nucleic acid therapeutics
Industry Biotechnology